GentiBio
GentiBio develops a modular engineering platform that produces stable, optimized T regulatory cells (Tregs) with specific IL-2 signaling for the treatment of autoimmune and inflammatory diseases. This technology addresses the limitations of existing Treg therapeutics by enabling scalable manufacturing and targeted delivery, enhancing efficacy and safety for patients.
- Biotechnology
Funding
Raised to date
$177MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Existing T regulatory cell (Treg) therapies for autoimmune and inflammatory diseases face challenges in scalable manufacturing, stability, and targeted delivery, which limits their efficacy and safety. Current methods struggle to produce a sufficient quantity of Tregs with the desired functional characteristics and the ability to reach the specific tissues affected by the disease.
Solution
GentiBio is developing a modular engineering platform to produce stable, optimized Tregs with specific IL-2 signaling for treating autoimmune and inflammatory diseases. The platform enables scalable manufacturing of Tregs with superior phenotypes tailored for specific diseases. By incorporating Treg-specific IL-2 signaling support, the platform simplifies manufacturing and allows for patient-specific dose titration. Furthermore, the platform facilitates tissue targeting for optimal efficacy and safety, addressing key limitations of existing Treg therapeutics.
Target Audience
The primary target audience includes patients with autoimmune and inflammatory diseases, as well as pharmaceutical companies and research institutions developing novel cell therapies.
Features
- Scalable engineering platform for producing stable Tregs with tailored phenotypes
- Treg-specific IL-2 signaling support to simplify manufacturing and enable patient-specific dose titration
- Tissue targeting capabilities for enhanced efficacy and safety
- Modular design allowing for customization of Tregs to address a wide variety of autoimmune, alloimmune, and inflammatory diseases